# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-220688
Filing Date
2026-05-13
Accepted
2026-05-13 08:30:23
Documents
14
Period of Report
2026-06-25

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | d137084ddef14a.htm iXBRL | DEF 14A | 407206
3 | GRAPHIC | g137084dsp012.jpg | GRAPHIC | 258818
4 | GRAPHIC | g137084dsp013.jpg | GRAPHIC | 166384
5 | GRAPHIC | g137084g68p04.jpg | GRAPHIC | 63831
| Complete submission text file | 0001193125-26-220688.txt |  | 1981197

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA | coya-20251231.xsd | EX-101.SCH | 6255
17 | EXTRACTED XBRL INSTANCE DOCUMENT | d137084ddef14a_htm.xml | XML | 5219

Mailing Address 12645 MEMORIAL DR., SUITE F1 #305 HOUSTON TX 77024
Business Address 12645 MEMORIAL DR., SUITE F1 #305 HOUSTON TX 77024 650.739.3939
Coya Therapeutics, Inc. (Filer) CIK: 0001835022 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41583 | Film No.: 26971056
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)